ArriVent BioPharma, Inc. Common Stock (AVBP) — Financial Flexibility Index
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Financial Flexibility Index of -1.42x as of June 2026. Free cash flow of $-39.58 Million (operating CF $-39.58 Million minus capex $0.00) represents -1% of total liabilities ($27.88 Million). Check AVBP intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ArriVent BioPharma, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of ArriVent BioPharma, Inc. Common Stock.
Annual Financial Flexibility Index for ArriVent BioPharma, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for ArriVent BioPharma, Inc. Common Stock. Explore AVBP cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $-12.59 Million | $1.82 Million | — |